BALTIMORE, June 20, 2011 (GLOBE NEWSWIRE) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has initiated research coverage of Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a leading health care provider of products to treat infection, enhance healing, and reduce the need for antibiotics.
In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines his investment thesis.
"In our view, Oculus is well-positioned to become the standard of care for treatment and irrigation of wound and skin care. By meeting unmet needs, the Company is enjoying phenomenal growth in multiple segments and appears to have the wind at its back."
To view a summary of the report or download the report in its entirety, please visit .
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock market research reports and weekly newsletters. For more information, visit .
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer. To download our research, disclosures, or for more information, visit .
About Oculus Innovative Sciences, Inc.: Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) is a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn(R) Technology platform, which significantly reduces the need for antibiotics while reducing infections and accelerating healing. The Microcyn Technology addresses the need for improved solutions in multiple markets including dermatology, oral care, cosmeceutical, wound care and others. It features a biocompatible, shelf-stable solution that is currently commercialized in the United States, Europe, India, China and Mexico and select Middle East countries under various country specific regulatory clearances and approvals. Several solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores; increase blood flow to the wound site; and reduce both inflammation and pain while assisting in faster wound closure. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. More information can be found at www.oculusis.com.
CONTACT: Goldman Small Cap Research Rob Goldman, Analyst 410-609-7100 firstname.lastname@example.org